Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up

Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with... Background Basal-like breast cancers, originally recognized by gene expression profiling, can be clinically identified using immunohistochemical (IHC) definitions that require estrogen receptor (ER) negativity. However, some basal cases are ER positive and are mistakenly considered to be luminal by standard IHC approaches, leading to suboptimal treatment choices. Nestin, an intermediate filament expressed in many stem cells, is a recently identified positive marker of basal-like pheno - type independent of ER status. In this study, we evaluated its clinical associations and prognostic capacity in a large breast cancer cohort. Methods A tissue microarray series of clinically annotated invasive breast cancers with 12.6-year median follow-up was assessed for nestin expression by IHC. Kaplan–Meier and Cox regression models were used to evaluate the prognostic sig- nificance of nestin status, for the primary endpoint of breast cancer-specific survival (BCSS). Results Among 3641 cases interpretable for nestin by IHC, positive staining was found in 371 cases (10%) and was signifi - cantly associated with poor prognostic factors including other markers of basal-like differentiation. Patients with nestin- positive tumors had a significantly lower 10 year BCSS (HR 1.97, 95% CI 1.62–2.40; P < 0.001). Importantly, within the large group of 2323 ER+ cases, nestin positivity identified a subgroup of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up

Loading next page...
 
/lp/springer_journal/nestin-expression-in-breast-cancer-association-with-prognosis-and-7JTi25EJ0S
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4583-z
Publisher site
See Article on Publisher Site

Abstract

Background Basal-like breast cancers, originally recognized by gene expression profiling, can be clinically identified using immunohistochemical (IHC) definitions that require estrogen receptor (ER) negativity. However, some basal cases are ER positive and are mistakenly considered to be luminal by standard IHC approaches, leading to suboptimal treatment choices. Nestin, an intermediate filament expressed in many stem cells, is a recently identified positive marker of basal-like pheno - type independent of ER status. In this study, we evaluated its clinical associations and prognostic capacity in a large breast cancer cohort. Methods A tissue microarray series of clinically annotated invasive breast cancers with 12.6-year median follow-up was assessed for nestin expression by IHC. Kaplan–Meier and Cox regression models were used to evaluate the prognostic sig- nificance of nestin status, for the primary endpoint of breast cancer-specific survival (BCSS). Results Among 3641 cases interpretable for nestin by IHC, positive staining was found in 371 cases (10%) and was signifi - cantly associated with poor prognostic factors including other markers of basal-like differentiation. Patients with nestin- positive tumors had a significantly lower 10 year BCSS (HR 1.97, 95% CI 1.62–2.40; P < 0.001). Importantly, within the large group of 2323 ER+ cases, nestin positivity identified a subgroup of

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Nov 20, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off